Back to search
FDAFDA · Food and drugs·Recall number D-925-2013

Benztropine Mesylate Injection, USP, 2 mg/mL(1 mg/1 mL), 2 mL Single Dose Vial, Rx only, Manufactured in the USA for Nexus Pharmaceuticals Inc, Lincolnshire, IL 60069, NDC 14789-300-02

Published September 4, 2013 · Recall initiated: August 1, 2013

Summary

FDA records drug Class II recall D-925-2013, published September 4, 2013 and initiated August 1, 2013. Recalling firm: Nexus Pharmaceuticals Inc; Status: Terminated; Reported quantity: 46,185 vials; Lot: a) Lot: 112911, Exp. 11/13, b) Lot: 030712, Exp. 3/14. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Presence of particulate matter: characterized as thin colorless flakes that are visually and chemically consistent with glass delamination.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Nexus Pharmaceuticals Inc
Distributor
Nationwide
Lot
a) Lot: 112911, Exp. 11/13, b) Lot: 030712, Exp. 3/14
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Benztropine Mesylate Injection, USP, 2 mg/mL(1 mg/1 mL), 2 mL Single Dose Vial, Rx only, Manufactured in the USA for Nexus Pharmaceuticals Inc, Lincolnshire, IL 60069, NDC 14789-300-02 recalled?

Yes. FDA published recall D-925-2013 on September 4, 2013. Reported hazard: Presence of particulate matter: characterized as thin colorless flakes that are visually and chemically consistent with glass delamination.

What should I do if I have this product?

Voluntary: Firm initiated · Letter